Lynparza granted Priority Review in the US for BRCA-mutated HER2-negative high-risk early breast cancer
First medicine targeting BRCA mutations to show clinical benefit in adjuvant settingAstraZeneca’s supplemental New Drug Application (sNDA) for Lynparza (olaparib) has been accepted and granted Priority Review in the US for the adjuvant treatment of patients with BRCA-mutated (BRCAm) HER2-negative high-risk early breast cancer who have already been treated with chemotherapy either before or after surgery. Lynparza is being jointly developed and commercialised by AstraZeneca and MSD. The Food and Drug Administration (FDA) grants Priority Review to applications for medicines that offer